Ensifentrine (Ohtuvayre) for COPD
Ensifentrine (Ohtuvayre) for COPD
August 19, 2024 (Issue: 1709)
The FDA has approved ensifentrine (Ohtuvayre –
Verona), an inhaled phosphodiesterase (PDE) 3 and
4 inhibitor, for maintenance treatment of chronic
obstructive pulmonary disease (COPD) in adults.
It is the first dual inhibitor of PDE3 and PDE4...more
- Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2023 report. Available at: www.goldcopd.org. Accessed August 1, 2024.
- Drugs for COPD. Med Lett Drugs Ther 2024; in press.
- H Zuo et al. Phosphodiesterases as therapeutic targets for respiratory diseases. Pharmacol Ther 2019; 197:225. doi:10.1016/j.pharmthera.2019.02.002
- A Anzueto et al. Ensifentrine, a novel phosphodiesterase 3 and 4 inhibitor for treatment of chronic obstructive pulmonary disease: randomized, double-blind, placebo-controlled, multicenter phase III trials (the ENHANCE trials). Am J Respir Crit Care Med 2023; 208:406. doi:10.1164/rccm.202306-0944oc
- Center for Drug Evaluation and Research. Risk assessment and risk mitigation review(s). Ensifentrine. June 12, 2024. Available at: https://bit.ly/4fsZ2ra. Accessed August 1, 2024.
- Inhibitors and inducers of CYP enzymes, P-glycoprotein, and other transporters. Med Lett Drugs Ther 2023 January 25 (epub). Available at: www.medicalletter.org/downloads/CYP_PGP_Tables.pdf.
- Approximate WAC for Ohtuvayre only; does not include cost for a nebulizer. WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. July 5, 2024. Reprinted with permission by First Databank, Inc. All rights reserved. ©2024. www.fdbhealth. com/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to
The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App
- FREE online per issue CME/CE
Purchase this article:
Title: Ensifentrine (Ohtuvayre) for COPD
Article code: 1709b
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
